Goodwill and Other Intangibles (Tables)

6 Months Ended

Jun. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of changes in the carrying amount of goodwill

Changes in the carrying amount of our goodwill for the six months ended June 30, 2020 were as follows (in thousands):

	Branded Pharmaceuticals		Sterile Injectables		Generic Pharmaceuticals		International Pharmaceuticals		Total
Goodwill as of December 31, 2019	$	828,818	$	2,731,193	$	—	$	35,173	$	3,595,184
Effect of currency translation	—		—		—		(2,387)		(2,387)
Goodwill impairment charges	—		—		—		(32,786)		(32,786)
Goodwill as of June 30, 2020	$	828,818	$	2,731,193	$	—	$	—	$	3,560,011

The carrying amounts of goodwill at June 30, 2020 and December 31, 2019 are net of the following accumulated impairments (in thousands):

	Branded Pharmaceuticals		Sterile Injectables		Generic Pharmaceuticals		International Pharmaceuticals		Total
Accumulated impairment losses as of December 31, 2019	$	855,810	$	—	$	3,142,657	$	500,417	$	4,498,884
Accumulated impairment losses as of June 30, 2020	$	855,810	$	—	$	3,142,657	$	512,376	$	4,510,843

Schedule of other intangible assets

Changes in the amount of other intangible assets for the six months ended June 30, 2020 were as follows (in thousands):

Cost basis:	Balance as of December 31, 2019		Acquisitions		Impairments		Other (1)		Effect of Currency Translation		Balance as of June 30, 2020
Indefinite-lived intangibles:
In-process research and development	$	93,900	$	—	$	—	$	—	$	—	$	93,900
Total indefinite-lived intangibles	$	93,900	$	—	$	—	$	—	$	—	$	93,900
Finite-lived intangibles:
Licenses (weighted average life of 14 years)	$	457,402	$	—	$	(8,700)	$	—	$	—	$	448,702
Tradenames	6,409		—		—		—		—		6,409
Developed technology (weighted average life of 11 years)	5,844,439		—		(55,051)		(104,531)		(11,310)		5,673,547
Total finite-lived intangibles (weighted average life of 11 years)	$	6,308,250	$	—	$	(63,751)	$	(104,531)	$	(11,310)	$	6,128,658
Total other intangibles	$	6,402,150	$	—	$	(63,751)	$	(104,531)	$	(11,310)	$	6,222,558
Accumulated amortization:	Balance as of December 31, 2019		Amortization		Impairments		Other (1)		Effect of Currency Translation		Balance as of June 30, 2020
Finite-lived intangibles:
Licenses	$	(410,336)	$	(4,295)	$	—	$	—	$	—	$	(414,631)
Tradenames	(6,409)		—		—		—		—		(6,409)
Developed technology	(3,414,138)		(217,440)		—		104,531		6,701		(3,520,346)
Total other intangibles	$	(3,830,883)	$	(221,735)	$	—	$	104,531	$	6,701	$	(3,941,386)
Net other intangibles	$	2,571,267									$	2,281,172

__________

(1)Other adjustments relate to the removal of certain fully amortized intangible assets.

Schedule of future amortization expense

For intangible assets subject to amortization, estimated amortization expense for the five fiscal years subsequent to December 31, 2019 is as follows (in thousands):

2020	$	426,483
2021	$	389,770
2022	$	375,039
2023	$	331,947
2024	$	293,417

Schedule of intangible asset impairment charges including goodwill

During the three and six months ended June 30, 2020 and 2019, the Company incurred the following goodwill and other intangible asset impairment charges (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Goodwill impairment charges	$	—	$	65,108	$	32,786	$	151,108
Other intangible asset impairment charges	$	—	$	21,699	$	63,751	$	100,399